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Background: Isolated limb perfusion (ILP) with tumor necrosis factor (TNF) and melphalan is
highly effective in treating limb-threatening soft tissue sarcoma (STS) and other bulky tumors.
Because of fear of TNF-associated toxicity, ILP with TNF is not offered to older patients in some
cancer centers, although especially in older patients, every attempt to avoid an amputation that may
end their independence must be considered.
Methods: Out of 306 TNF-based ILPs, 50 ILPs were performed for limb salvage in 43 patients
75 years old (range, 75–91 years): 29 STS and 14 melanoma patients.
Results: In the STS patients, a response rate of 76% and a limb-salvage rate of 76% were
achieved; in the melanoma patients, a 100% response rate and a 93% limb-salvage rate were
achieved. Local toxicity was mild. The three postoperative deaths that occurred in the total series of
306 TNF-based ILPs in Rotterdam (1%) occurred in patients 75 years old after leakage-free
perfusions and were not related to TNF but to extremely high-risk profiles in these three patients.
Conclusions: Older patients should not be withheld a TNF-based ILP for limb salvage, because
the procedure is safe and highly effective in these patients.
Isolated limb perfusion (ILP) is a technique of cancer
treatment that delivers high doses of cytostatic drugs to a
tumor-bearing extremity that is isolated from the sys-
temic circulation and connected to a heart-lung ma-
chine.1 By ILP, regional concentrations of chemothera-
peutic agents 15 to 20 times higher than those reached
after systemic administration can be achieved without
systemic toxicity.2 In the management of locally ad-
vanced soft tissue sarcoma (STS), limb salvage is a
major challenge. In patients with multiple and/or bulky
in-transit melanoma metastases, obtaining local control
is a major challenge. In contrast to the inefficacy of ILP
with melphalan alone in the management of irresectable
extremity STS, with response rates of only 10% to
35%,3,4 the introduction of tumor necrosis factor-
(TNF) in combination with melphalan in ILP has been
reported in a European multicenter trial; it resulted in re-
sponse rates 80% and limb-salvage rates 70% in
STS.5,6 These results led to the approval of TNF in Europe.7
Also, in the management of in-transit metastases, TNF
seems to improve complete response (CR) rates,8 especially
in patients with bulky tumors and in patients whose previ-
ous ILP with melphalan alone failed, as has been demon-
strated by reports from the Surgery Branch of the National
Cancer Institute in the United States.9,10
The incidence of STS increases rapidly above the age
of 50 years. Approximately 18% of the patient popula-
tion is above the age of 70 years.4 The incidence of
malignant melanoma has more than doubled over the last
20 years.12 For both men and women, rates increased
relatively more in the older age groups. As a conse-
quence of these epidemiological features, we are con-
fronted with a large group of elderly patients who might
need a limb-saving procedure such as ILP. These pa-
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tients, especially, will be severely limited in their mobil-
ity and lose independence when amputation of a limb has
to be performed. Therefore, especially in the elderly,
every attempt to avoid amputation must be considered,
and a TNF-based ILP must be considered despite the age
of the patients. The perception that TNF-based ILP is a
risky endeavor has been demonstrated to be false pro-
vided that leakage is monitored and well controlled.13
But even in the event of significant leakage, we have
demonstrated that with correct fluid management and
postoperative care, patients do not develop major or
life-threatening complications.14 Therefore we do not
think it is reasonable to consider age a limiting factor for
patients to undergo a TNF-based ILP. Here we present
our single Rotterdam institution experience in a large
series of patients aged 75 years with irresectable STS
or in-transit melanoma metastases of an extremity. These
patients were all treated by ILP with high-dose TNF and
melphalan.
PATIENTS AND METHODS
ILP Methodology
We have described the procedure of the current TNF-
based ILP previously.1,2 In brief, isolation of the blood
circuit of a limb is achieved by clamping and cannulating
the major artery and vein, connecting to an oxygenated
extracorporeal circuit, ligating collateral vessels, and ap-
plying a tourniquet. Once isolation is secured, drugs can
be injected into the perfusion circuit.
Drugs
Recombinant human TNF- (4.9–5.8  107 U/mg)
was administered at doses of 2 to 4 mg in the perfusion
circuit; recombinant human interferon- (IFN; .2 mg or
1.5  106 U/ampoule) was administered in the ILPs
performed in the period 1991 to 1993 on days 2 and
1 subcutaneously and on day 0 into the perfusion
circuit. Both TNF and IFN were obtained from Boehr-
inger Ingelheim GmbH (Ingelheim/Rhein, Germany).
Melphalan (L-phenylalanine mustard; Alkeran™; Bur-
roughs Wellcome, London, UK) was obtained as a sterile
powder (100 mg) that was dissolved aseptically by using
solvent and diluent provided by Burroughs Wellcome
(London, UK). Because of its efficacy and low regional
toxicity profile, melphalan is the standard drug, most
commonly used at a dose of 10 mg/L of perfused tissue
for a leg and 13 mg/L for an arm. The perfusate is heated
to 39°C to 40°C to achieve mild hyperthermia tissue
temperatures in the limbs, to be kept stable at 39°C.
Radiolabeled albumen is injected into the extracorporeal
circuit so that leakage into the systemic circulation can
be detected with a precordial scintillation probe.15 Leak-
age monitoring is mandatory, especially now that high
doses of TNF are used in the treatment of STS and
melanomas. After 1.5 hours of perfusion, the limb is
rinsed with an electrolyte solution, cannulas are re-
moved, and the vessels are repaired. Classification of
postoperative limb toxicity was performed according to
Wieberdink et al.16: grade I, no reaction; grade II, slight
erythema, edema, or both; grade III, considerable ery-
thema and/or edema with some blistering, slightly dis-
turbed motility permissible; grade IV, extensive epider-
molysis and/or obvious damage to the deep tissues,
causing definite functional disturbances; threatening or
manifest compartmental syndrome; and grade V, reac-
tion that may necessitate amputation.
Patients
At the Erasmus University Medical Center-Daniel den
Hoed Cancer Center, 306 TNF-based ILPs were per-
formed in STS patients (224 ILPs) and melanoma pa-
tients (82 ILPs) between 1991 and 2001. In 43 patients
(14 men and 29 women) older than 75 years, 50 TNF-
based ILPs were performed. Twelve patients also re-
ceived .2 mg of IFN subcutaneously on the 2 days
before the ILP as well as .2 mg of IFN in the perfusion
circuit during ILP. All ILP and follow-up data in our
institution are recorded prospectively in a database. Pa-
tient and ILP characteristics, treatment results, and fol-
low-up data are listed in Table 1 for STS or other
nonmelanoma limb-threatening tumors and in Table 2
for melanoma. The mean age of this selected group of
patients was 79 years (range, 75–91 years). Twenty-nine
patients with irresectable STS or other limb-threatening
tumors of the leg (n 19) or arm (n 10) underwent 34
ILPs (Table 1). Nineteen were treated for primary tumors
and 10 for recurrences. In this group, the median size of
single tumors (n 20) was 10 cm (range, 6–38 cm), and
for multifocal tumors (n  9) it was 5 cm (range, 1–20
cm). Two patients with Stewart-Treves syndrome had
undergone three ILPs each. One patient underwent two
perfusions. Fourteen patients with in-transit melanoma
metastases (all lower extremity) underwent 16 ILPs (Ta-
ble 2). Two patients underwent two ILPs.
RESULTS
Sarcomas and Nonmelanoma
Limb-Threatening Tumors
In the STS group, all patients but two (postoperative
deaths) were evaluated for response by magnetic reso-
nance imaging (MRI) and histopathologic evaluation of
the tumor resection specimen after response to the ILP.
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CRs were defined as clinical MRI-proven CRs, which
were not operated on a second time, and clinical MRI-
proven partial responses (PRs) that, after resection, were
demonstrated to be 100% necrotic and were classified as
histopathologic CRs. PRs were defined as tumors that
underwent shrinkage of 50% or, in case of 50%
clinical shrinkage, revealed a 50% necrosis on resec-
tion. The overall response rate (CR plus PR) was 76%,
consisting of 38% CR and 38% PR. No change, defined
as 50% tumor shrinkage and 50% necrosis, was seen
in 18% of the patients. None of the patients had disease
progression within 3 months of the ILP (Table 1).
In the soft tissue patient population, 31% of patients
had multiple sarcomas and were not candidates for re-
sections after ILP. In the patients with a single sarcoma,
resection was made possible by the induction treatment
with ILP and was performed in 16 of 20 patients at a
median of 2.5 months after ILP. ILP and surgical treat-
ment resulted in limb salvage in 22 (76%) of 29 patients
after a median follow-up of 18 months. Amputation was
performed in 7 of 29 patients. In three patients (all with
multiple sarcomas in the extremity), repeated ILP was
performed after a median of 20 months (range, 13–24
months) after prior ILP. In the sarcoma group, despite
TABLE 1. Characteristics of 29 patients with irresectable STS or other limb-threatening tumors at the time of ILP (n  34)
with TNF and melphalan
Patient
No. Sex
Age
(y) Histology
Grade
(1–3) Site
No.
Tumors P/R
Type
of ILP
Local toxicity
(Wieberdink) (I–V)
Clinical
response
Histological
response
(% necrosis)
Final
outcome
Limb
salvage
Dead (D)
or alive (A)
Follow-up
(mo)
1a F 78 Angiosarcoma 2 Lo arm 100 R Brach 2 CR ND CR
F 80 Angiosarcoma 2 Lo arm 100 RR Axil 2 CR ND CR
F 82 Angiosarcoma 2 Lo arm 100 RR Axil 3 PR ND PR Y D 47
2 F 75 Liposarcoma 1 Lo arm 1 R Brach 3 CR ND CR Y A 85
3 F 82 Leiomyosarcoma 2 Up arm 1 P Brach 2 PR 70 PR Y D 57
4 F 82 Mal Fibr Hist 3 Up leg 1 P Iliac 3 NC ND NC Y D 6
5 F 83 Liposarcoma 3 Up leg 2 P Iliac 2 PR 90 PR Y A 55
6a F 81 Mal Fibr Hist 2 Lo leg 4 R Popl 2 NC ND NC
F 82 Mal Fibr Hist 2 Lo leg 6 RR Fem 2 CR ND CR N D 22
7 F 78 Pleiomorfsarc 3 Fos popl 1 R Iliac 2 NC ND NC N D 14
8b M 91 Liposarcoma 3 Fos popl 1 P Iliac 2 ND ND ND Y D 0
9 F 87 Leiomyosarcoma 2 Foot 1 R Popl 2 NC ND NC Y D 8
10 M 76 Leiomyosarcoma 3 Lo arm 1 P Brach 4 PR 90 PR Y A 43
11 M 75 Clear cell tumor 3 Up  lo leg 3 R Iliac 3 CR 100 CR Y D 9
12 F 75 Mal Fibr Hist 2 Lo foot 1 R Fem 3 NC 90 PR Y D 3
13 M 83 Extraskeletal
osteosarcoma
3 Up leg 1 P Iliac 3 NC 90 PR Y D 9
14b M 76 Squamous cell NA Lo arm 3 R Axil 4 ND ND ND Y D 0
15 F 77 Leiomyosarcoma 3 Fos popl 1 P Popl 2 PR 90 PR Y A 239
16a F 77 Angiosarcoma 2 Lo Arm 30 P Brach 3 CR ND CR
F 78 Angiosarcoma 2 Up  lo arm 20 R Axil 2 CR ND CR
F 80 Angiosarcoma 2 Up  lo arm 10 RR Axil 1 CR ND CR Y A 46
17 F 83 Mal Fibr Hist 3 Lo leg 3 R Popl 2 PR 50 PR N D 26
18 F 76 Angiosarcoma 1 Lo arm 21 P Brach 3 CR 100 CR Y A 21
19 M 83 Synoviosarcoma 2 Up leg 1 R Iliac 2 CR ND CR N A 28
20 F 76 Schwannoma 3 Up leg 1 P Iliac - NC 50 NC Y A 26
21 M 79 Schwannoma 3 Lo arm 1 P Brach 2 PR 10 PR Y A 10
22 F 77 Kapos sarcoma 1 Lo leg 30 P Fem 1 CR 100 CR N A 18
23 M 81 Mal Fibr Hist 3 Lo arm 1 P Brach 1 NC 50 NC Y A 17
24b M 76 Undifferentiated
carcinoma
2 Up leg 1 P Iliac 2 CR 100 CR N D 0
25 M 75 Liposarcoma 3 Fos popl 1 P Iliac 2 NC 50 PR N A 11
26 M 81 Epitheloid sarcoma 3 Lo leg 1 P Fem 1 PR 90 PR Y A 8
27 F 78 Angiosarcoma 1 Total arm 20 P Axil 2 CR ND CR Y A 6
28 M 80 Squamous cell NA Hand 1 P Brach 2 PR ND PR Y A 3
29 M 86 Mal Fibr Hist 3 Lo leg 1 P Fem 2 PR ND PR Y A 3
Mean 79.5 CR38% 22/29  76% 26.0
Median 78 PR 38% 18.0
Up arm, upper arm; Lo arm, lower arm; Up leg, upper leg; Lo leg, lower leg; Fos Popl, fossa poplitea; Fem, femoral ILP; Popl, popliteal ILP; Axil,
axilar ILP; Brach, brachial ILP; P, primary; R, recurrence; RR, re-recurrence; CR, complete response; PR, partial response; NC, no change; NA, not
applicable; ND, not determined; ILP, isolated limb perfusion; Mal Fibr Hist, malignant fibrous histiocytoma. Overall Response rate is 76% (CR 38%,
PR 38%).
a These have undergone multiple perfusions.
b Patient died after surgery.
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multiple tumors being present in 31% of the sarcoma
patient population, local recurrence–free survival at 2
years was 50%. Despite the median age of 78 years, 50%
of all patients were still alive at 4 years.
Patients With Multiple or Bulky Melanoma
In-Transit Metastases
In the melanoma patients, an overall response rate of
100% was achieved; this consisted of 75% CR and 25%
PR. Therefore, all patients responded, and no stable
disease or disease progression was observed. This re-
sulted in a 93% limb salvage at a median follow-up of 16
months. The single amputation in this group (patient 4;
Table 2) was not tumor related but was caused by severe
arteriosclerosis more than 14 months after the last ILP.
Two patients underwent a second perfusion 19 and 25
months after the first ILP. Both resulted in a CR after the
repeated ILP. In the melanoma patients, no postoperative
deaths occurred. Local progression–free survival in the
melanoma population was almost 1 year. Despite the
median age of 78 years, 33% of all patients were still
alive at 5 years.
Local Toxicity
In 96% of the perfusions, only mild to moderate
(Wieberdink grade I–III) local toxicity was observed. In
none of the patients did an amputation have to be per-
formed because of TNF- or melphalan-related toxicity
after ILP. Only in the patient with a large ulcerating
undifferentiated carcinoma metastasis in the upper leg,
which became completely necrotic after the ILP and
subsequently became infected, did a post-ILP amputation
have to be undertaken, because the metastasis was the
source of (eventually fatal) sepsis.
Leakage Control and Systemic Toxicity
Leakage Control
The median leakage rate was 0% (range, 0%–20%) in
the 50 ILPs described in this series. In the sarcoma group
of 34 ILPs, there were 26 ILPs with 0% leakage, 5 with
7% leakage, and 3 with significant leakage of 19%,
20%, and 20%. In the melanoma group of 16 ILPs, there
were 10 ILPs with 0% leakage and 3 with 5% leakage.
There were three ILPs with significant leakage of 10%,
12%, and 13%. None of these six patients with 10% to
20% leakage experienced grade 3 or 4 hypotension or
any other form of grade 3 or 4 toxicity.
Systemic Toxicity
Most patients went through a slightly hyperdynamic
postoperative period, which usually lasted 2 to 6 hours,
with slightly increased heart rates and temperatures as a
reaction to the circulating TNF immediately after the
ILP. No major toxicity was observed in the immediate
postoperative phase in any of the 43 older patients.
TABLE 2. Characteristics of 14 patients with in-transit melanoma metastases at the time of ILP (n  16) with TNF
and melphalan
Patient
No. Sex
Age
(y) Site
No.
Tumor
Type of
ILP
Local toxicity
(Wieberdink) (I–V)
Final
outcome
Dead (D)
or alive (A)
Follow-up
(mo)
1a F 78 Lo leg 20 Fem 2 CR
F 80 Tot leg 100 Iliac 2 CR A 132
2 F 76 Tot leg 100 Iliac 2 CR D 10
3 F 75 Lo leg 10 Popl 3 CR D 4
4ab F 82 Lo leg 20 Popl 2 PR
F 83 Lo leg 100 Iliac 3 CR D 44
5 F 77 Lo leg 10 Iliac 2 PR D 11
6 F 76 Tot leg 50 Iliac 2 CR D 45
7 F 75 Lo leg 50 Iliac 1 CR D 21
8 F 76 Lo leg 10 Popl 2 CR D 16
9 F 80 Tot leg 10 Iliac 2 CR A 46
10 F 78 Lo leg 10 Fem 2 CR A 40
11 F 79 Foot 50 Fem 2 CR A 17
12 F 82 Lo leg 20 Fem 3 PR A 3
13 M 77 Lo leg 20 Iliac 3 PR A 3
14 F 91 Lo leg 100 Fem 2 CR A 3
Mean 78.7 CR 75% 27.0
Median 78 PR 25% 16
Abbreviations: Lo leg, lower leg; tot leg, total leg; Fem, femoral ILP; Popl, popliteal ILP; CR, complete response; PR, partial response; ILP, isolated
limb perfusion; TNF, tumor necrosis factor. Overall Response rate is 100% (CR 75%, PR 25%).
a Patients who have undergone multiple perfusions (n  2).
b This patient underwent an above-knee amputation of the limb because of arterioscelosis more than 1 year after the last perfusion.
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One patient with a history of multiple myocardial
infarction and angina pectoris (patient 19; Table 1) de-
veloped a postoperative myocardial infarction. The ILP
was associated with a leakage rate of 3%, and the post-
operative course was associated with grade 2
hypotension.
Except in the patient (patient 8; Table 1) who devel-
oped a thrombosis of the mesenteric artery 3 days after
the ILP and in the patient (patient 24; Table 1) who
developed septic shock because of infection of the mas-
sive necrosis of a large ulcerated tumor mass 10 days
after the ILP, no grade 2, 3, or 4 toxicity was observed
with respect to liver function, renal function, or shock-
like symptoms. Temporary mild fever (World Health
Organization grade II or III) occurred after 32 of the 50
perfusions.
Complications
In the total series of 306 TNF-based ILPs performed
between 1991 and 2001 in the Daniel den Hoed Cancer
Center, three patients died from postoperative complica-
tions. All three patients were 75 years old. Two pa-
tients with a high-risk cardiovascular status and history
died because of cardiovascular complications: a 91-year-
old patient (patient 8; Table 1) developed a thrombosis of
the mesenteric artery 3 days after the ILP, with a fatal
outcome. A 76-year-old patient (patient 14; Table 1) with
a history of prior cerebrovascular accidents died from a
massive cerebrovascular accident on day 3 after an un-
eventful and leakage-free ILP. A cardiovascular compli-
cation also occurred in an 83-year-old patient (patient 19;
Table 1). This patient had a history of multiple myocar-
dial infarctions and angina pectoris and developed a
postoperative myocardial infarction after yet another
well-controlled ILP with a leakage rate of 3% and no
significant postoperative hypotension. The third patient
who died in the postoperative phase (patient 24; Table 1)
developed immediate and total necrosis of a very large
ulcerating undifferentiated carcinoma metastasis in the
upper leg. This necrotic mass became infected, and the
patient developed septic shock. Despite an amputation
and optimal medical management, the patient died of
sepsis.
DISCUSSION
In elderly people, amputation of a limb has a major
effect on their independence and daily activities. How-
ever, older patients with irresectable STS or recurrent
melanoma of the extremities are often subjected to am-
putation because the risk of an ILP is considered to be
too high. Here we demonstrated that ILP is very efficient
in achieving limb salvage and local tumor control in
elderly patients, with acceptable morbidity and mortality.
In the face of imminent amputation or unacceptable loss
of control over locoregional tumor growth in melanoma
patients, we have not turned down any patient above the
age of 75 years for a TNF-based ILP. Thus, we have
accepted the considerable risk associated with this posi-
tion. Here we report on the largest single-institution
experience with the efficacy and risks of TNF-based ILP
in elderly patients. Out of 306 TNF-based ILPs, 50 ILPs
were performed in this patient population with the goal
of avoiding amputation, which more than in any other
age group determines the independence and quality of
how these patients can continue their lives.
Until several years ago, TNF was thought be inappli-
cable in a clinical setting because of its severe toxicity
when administered systemically. However, in an isolated
perfusion setting, it can be used very safely and is ex-
tremely efficient in inducing tumor responses when com-
bined with cytostatic agents. We have demonstrated that
this extremely potent synergy is based on the selective
vasodestruction of the tumor-associated vasculature,5,17
as well as on the greatly enhanced uptake of melphalan
or any other chemotherapeutic drug in the tumor when
combined with TNF in the ILP setting.18,19
Safe administration of TNF is guaranteed because we
use continuous leakage monitoring and adequate hydra-
tion of patients. These components are both essential in
the management of possible TNF-related toxic side ef-
fects.10 The median leakage during ILP was0% (range,
0%–20%). Even in cases with leakage, this can be man-
aged very well. We previously described a series of
patients with leakage from 12% to 65%. No fatal com-
plications occurred, and only a few shocks were ob-
served, which could be managed without intubation and
with little need for vasopressor support.11 Also in case of
leakage, adequate hydration turned out to be the key in
the treatment of TNF-related toxicity.
Also, in this group of older patients, ILP can be
performed safely, without severe toxicity and morbidity.
In this patient group, with a mean age of 79 years, the
overall perioperative mortality was low, and the local
toxicity was Wieberdink grade II or III in the vast ma-
jority of patients. Vrouenraets et al.20 recently reported
on regional toxicity after ILP with TNF and demon-
strated that increasing age was not correlated with more
severe toxicity. The median hospital stay in this patient
population of elderly patients after ILP was approxi-
mately 2 weeks. In the postoperative period, most pa-
tients were completely mobilized and left the hospital
without severe functional impairment.
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The response rates and limb salvage percentages were
comparable to those in ILP studies in younger STS
patients.1 In melanoma patients, the locally advanced
bulky tumors, in particular, may cause such pain, hem-
orrhage, or vascular compression that amputation of the
affected limb sometimes has to be considered. ILP with
TNF and melphalan is an effective method to achieve
local tumor control and thereby is of great antimorbidity
value. It is regarded as the treatment of choice in bulky
cases of melanoma or treatment failures after ILP with
melphalan alone. The 3 deaths reported in this series are
the only 3 postoperative deaths that we encountered in
the 306 patients treated with TNF-based ILP in Rotter-
dam between 1991 and 2001, and this reflects the risks
that have been accepted in this patient population. Two
patients had extensive cardiovascular disease. The third
patient died from sepsis caused by the infection of a
totally necrotic massive tumor, which was confirmed to
be a histopathologic CR, in the upper leg after ILP. The
fact that this rapid tumor had penetrated the skin and was
ulcerating should have kept us from performing the per-
fusion, because there was no way that infection of this
necrotic mass could have been prevented. The fact that
the complications occurred after leakage-free ILPs fur-
ther underlines the point that the complications were due
to patient-specific risks and not to uncontrolled elements
of the ILP. We want to emphasize, however, that ade-
quate experience with the procedure and the status of
reference centers for TNF-based ILP are a prerequisite to
deal successfully with these patients.
This series of older patients with limb-threatening
sarcomas or multiple in-transit melanoma metastases
demonstrates the safe and efficient use of TNF-based
ILP. It results in high response rates and, thereby, high
limb-salvage rates and very good local tumor control
rates in both the sarcoma and the melanoma patients.
Older patients should be offered and not be withheld a
TNF-based ILP for limb salvage.
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